Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
45.16
-1.21 (-2.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corp ADR
< Previous
1
2
3
Next >
Legend Biotech Establishes Strategic Advisory Board
April 03, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
March 30, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
February 24, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
February 21, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
January 27, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
January 03, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
January 02, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
November 21, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
November 04, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
November 03, 2022
From
Legend Biotech Corporation
Via
Business Wire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
September 27, 2022
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
September 15, 2022
From
Legend Biotech Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
August 19, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
August 05, 2022
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
August 04, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Corporation Announces Pricing of Public Offering
July 26, 2022
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Corporation Announces Proposed Public Offering
July 25, 2022
From
Legend Biotech Corporation
Via
Business Wire
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
June 04, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
June 03, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
June 01, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022
From
Legend Biotech
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 26, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
May 18, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
May 09, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
May 06, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Appointment of Global Head of Research and Early Development
April 01, 2022
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
March 25, 2022
From
Legend Biotech
Via
Business Wire
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
March 23, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 18, 2022
From
Legend Biotech
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.